New bronchitis pill aims to quiet coughs faster
NCT ID NCT07198347
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an experimental drug called AG2001 in 300 adults with acute bronchitis. Participants take the drug three times daily for 7 days. The goal is to see if AG2001 reduces cough and mucus better than two other active drugs by day 4. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AG2001 (an experimental drug for bronchitis)
- What this could lead to
- If successful, AG2001 could offer a new treatment option that reduces cough and mucus in acute bronchitis more effectively than current medications.
- What could go wrong
- This is an early Phase 3 trial with only 300 participants, so results may not apply to everyone. The drug may not prove superior to existing treatments, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE BRONCHITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug raphamin aims to shorten bronchitis suffering
- New bronchitis drug shows promise in large trial
- 230,000 patient records reveal antibiotic prescribing patterns for lung infections
- Info sheets may curb unnecessary antibiotics for colds and sore throats
- New study aims to curb antibiotic overuse for coughs and colds
- Herbal remedy may speed bronchitis recovery